At Biopôle since 2016.
Novassay is engaged in R&D programs targeting neuropathic pain, aiming to bring to the clinic small molecule therapeutics as well as humanized monoclonal antibodies. Our immediate target is the Voltage Gated Calcium Channels (VGCC), which is a validated mediator in neuropathic pain. In addition, Novassay has developed technologies and research tools which are made available for R&D discovery work and not for human use.
Our second activity relates to an exploratory/discovery program to ascertain and validate VGCC as therapeutic target in solid tumors over-expressing CACNA2D1 within a Tumor Initiating Cell (TIC) sub-population. These TICs (Cancer Stem Cells) are believed to be driving the metastatic potential of specific solid tumor types.